Management of sepsis during the early "golden hours"

被引:69
作者
Raghavan, Murugan
Marik, Paul E.
机构
[1] Thomas Jefferson Univ, Div Pulm & Crit Care Med, Philadelphia, PA 19107 USA
[2] Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA USA
关键词
severe sepsis; septic shock; sepsis syndrome; critical illness; early resuscitation; golden hour;
D O I
10.1016/j.jemermed.2006.05.008
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Severe sepsis and septic shock are common causes of morbidity and mortality. Interventions directed at specific endpoints, when initiated early in the "golden hours" of patient arrival at the hospital, seem to be promising. Early hemodynamic optimization, administration of appropriate antimicrobial therapy, and effective source control of infection are the cornerstones of successful management. In patients with vasopressor-dependent septic shock, provision of physiologic doses of replacement steroids may result in improved survival. Administration of drotrecogin alfa (activated), (activated protein C) has been shown to improve survival in patients with severe sepsis and septic shock who have a high risk of mortality. In this article we review the multi-modality approach to early diagnosis and intervention in the therapy of patients with severe sepsis and septic shock. (C) 2006 Elsevier Inc.
引用
收藏
页码:185 / 199
页数:15
相关论文
共 205 条
[11]  
BARCLAY SA, 1987, INTENS CARE MED, V13, P114
[12]   MULTIPLE ORGAN FAILURE SYNDROME IN THE 1990S - SYSTEMIC INFLAMMATORY RESPONSE AND ORGAN DYSFUNCTION [J].
BEAL, AL ;
CERRA, FB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (03) :226-233
[13]   Bedside ultrasonography in the ICU - Part 1 [J].
Beaulieu, Y ;
Marik, PE .
CHEST, 2005, 128 (02) :881-895
[14]  
Bellomo R, 2000, LANCET, V356, P2139
[15]   Measurements of catecholamine-mediated apoptosis of immunocompetent cells by capillary electrophoresis [J].
Bergquist, J ;
Josefsson, E ;
Tarkowski, A ;
Ekman, R ;
Ewing, A .
ELECTROPHORESIS, 1997, 18 (10) :1760-1766
[16]   Extended evaluation of recombinant human activated protein C United States trial (ENHANCE US) - A single-arm, phase 313, multicenter study of drotrecogin alfa (activated) in severe sepsis [J].
Bernard, GR ;
Margolis, BD ;
Shanies, HM ;
Ely, EW ;
Wheeler, AP ;
Levy, H ;
Wong, K ;
Wright, TJ ;
Ahmed, M ;
Albertson, T ;
Anas, N ;
Astiz, M ;
Bacon, A ;
Bandi, V ;
Booth, F ;
Bray, W ;
Brilli, R ;
Carlson, R ;
Cheatham, M ;
Conrad, S ;
Cooney, R ;
Cox, M ;
Dolich, M ;
Dries, D ;
Fang, R ;
Forse, R ;
Fricker, R ;
Givens, C ;
Gomez, C ;
Gottlieb, J ;
Graham, D ;
Cropper, I ;
Cross, T ;
Harrison, N ;
Kearl, R ;
Kearney, P ;
Kinasewitz, G ;
Kruse, J ;
Lamberti, J ;
Levy, M ;
Light, R ;
Lin, L ;
Lisco, S ;
Lo, T ;
Linda, L ;
Lodato, R ;
Malave, L ;
Martinez, A ;
Mastuschak, G ;
McDermott, L .
CHEST, 2004, 125 (06) :2206-2216
[17]   Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis [J].
Bernard, GR .
CRITICAL CARE MEDICINE, 2003, 31 (01) :S85-S93
[18]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[19]   INHIBITORS OF COMPLEMENT AND NEUTROPHILS - A CRITICAL-EVALUATION OF THEIR ROLE IN THE TREATMENT OF SEPSIS [J].
BONE, RC .
CRITICAL CARE MEDICINE, 1992, 20 (06) :891-898
[20]   THE ACCP-SCCM CONSENSUS CONFERENCE ON SEPSIS AND ORGAN FAILURE [J].
BONE, RC ;
SIBBALD, WJ ;
SPRUNG, CL .
CHEST, 1992, 101 (06) :1481-1482